Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 191 to 200 of 1090 total matches.

Mirtazapine - A New Antidepressant

   
The Medical Letter on Drugs and Therapeutics • Dec 20, 1996  (Issue 990)
Psychopharmacol, 10 suppl 4:37, 1995). DRUG INTERACTIONS — In vitro studies indicate that mirtazapine ...
Mirtazapine (mir taz a peen; Remeron - Organon) has been approved by the US Food and Drug Administration for treatment of depression. A tetracyclic piperazinoazepine, it is an analog of mianserin, an antidepressant available in Europe, but is structurally unrelated to antidepressants previously available in the USA.
Med Lett Drugs Ther. 1996 Dec 20;38(990):113-4 | Show Introduction Hide Introduction

In Brief: Orlistat OTC for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007  (Issue 1263)
, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D. CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D ...
The FDA has approved over-the-counter (OTC) sale of the weight-loss drug orlistat (Xenical – Roche)1 as alli (GlaxoSmithKline), to be used in combination with a reduced-calorie, low-fat diet. Orlistat binds to gastric and pancreatic lipases, preventing absorption of about 30% of dietary fat with the 120-mg prescription dose, and 25% with the 60-mg OTC dose. A 16-week controlled trial of the OTC dose (60 mg 3 times daily with meals) in overweight, not obese, patients (average BMI 26.8) on a reduced-calorie, low-fat diet found that patients taking the drug lost 1.15 kg more than those taking...
Med Lett Drugs Ther. 2007 Jun 18;49(1263):49 | Show Introduction Hide Introduction

In Brief: Anaphylaxis with Omalizumab (Xolair)

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007  (Issue 1265)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D., University of Washington ADVISORY BOARD: Jules ...
The FDA has received new reports of serious and life-threatening hypersensitivity reactions to omalizumab (Xolair – Genentech), a monoclonal anti-IgE antibody injected subcutaneously for treatment of asthma (Med Lett Drugs Ther 2003; 45:67), and has added a black-box warning to the package insert.Postmarketing reports submitted to the FDA included 124 reports of anaphylaxis among an estimated 57,300 patients (0.2%) who might have been treated with the drug between June 2003 and December 2006. Anaphylaxis occurred after the first dose of Xolair in 39% of cases, after a 2nd dose in 19%, after...
Med Lett Drugs Ther. 2007 Jul 16;49(1265):59 | Show Introduction Hide Introduction

Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007  (Issue 1276)
Issue 1276 December 17, 2007 DRUG INTERACTIONS — Inhibitors and inducers of CYP3A4 can affect ...
Temsirolimus (Torisel - Wyeth), an mTOR (mammalian target of rapamycin) kinase inhibitor that is metabolized to sirolimus (rapamycin), has been approved by the FDA for intravenous treatment of advanced renal cell carcinoma.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):103-4 | Show Introduction Hide Introduction

Linezolid (Zyvox)

   
The Medical Letter on Drugs and Therapeutics • May 29, 2000  (Issue 1079)
. DRUG INTERACTIONS — Linezolid is a weak, non-selective reversible inhibitor of monoamine oxidase ...
Linezolid, the first of a new class of antibiotics, the oxazolidinones, has been marketed for treatment of infection due to vancomycin-resistant Enterococcus faecium, nosocomial and community-acquired pueumonia due to Staphylococcus aureus or penicillin-sucsceptible Streptococcus pneumoniae, and skin and skin structure infections, including those due to methicillin-resistant S. aureus (MRSA).
Med Lett Drugs Ther. 2000 May 29;42(1079):45-6 | Show Introduction Hide Introduction

Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
cause heart failure, interacts with many other drugs, and is very expensive. Long-term data are needed ...
The FDA has approved mavacamten (Camzyos – MyoKardia/BMS), a modulator of cardiac myosin, to improve functional capacity and symptoms in adults with New York Heart Association (NYHA) class II or III obstructive hypertrophic cardiomyopathy (HCM) who have a baseline left ventricular ejection fraction (LVEF) ≥55%. Mavacamten is the first drug in its class to become available in the US.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):89-91 | Show Introduction Hide Introduction

Caspofungin (Cancidas) For Aspergillosis

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001  (Issue 1108)
Echinocandins antifungals amphotericin B Fungizone Itraconazole Sporanox Drug interactions with caspofungin ...
Caspofungin acetate(Cancidas) is the first of a new class of antifungals, the echinocandins. It has been approved by the FDA for treatment of invasive aspergillosis in patients who fail to respond to or are unable to tolerate other antifungal drugs such as amphotericin B and itraconazole.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):58-9 | Show Introduction Hide Introduction

In Brief: Cetirizine OTC

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008  (Issue 1277)
, M.D., Albert Einstein College of Medicine CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten ...
Cetirizine (Zyrtec, and others) and cetirizine/pseudoephedrine (Zyrtec-D) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine (Claritin, and others) was the first.Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers (W Carey et al. Drugs Exp Clin Res 2002; 28:243), but no well-controlled clinical trials have established that any...
Med Lett Drugs Ther. 2008 Jan 14;50(1277):1 | Show Introduction Hide Introduction

In Brief: Herbal Warning

   
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008  (Issue 1279)
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten, Pharm.D.,University of Washington ADVISORY BOARD ...
The FDA recently advised health care professionals and consumers not to use a number of dietary supplements found to contain the phosphodiesterase-5 inhibitor sildenafil (Viagra) or an analog of the drug (www.fda.gov). Although the effects of sildenafil may be noticeable (in men), the presence of other, possibly more toxic adulterants in dietary supplements may be more difficult or impossible to detect.Other drugs previously found in dietary supplements have included lovastatin (Mevacor, and others), estrogen, alprazolam (Xanax, and others), indomethacin (Indocin, and others) and warfarin...
Med Lett Drugs Ther. 2008 Feb 11;50(1279):9 | Show Introduction Hide Introduction

The Medical Letter - 50th Anniversary

   
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009  (Issue 1304)
and Japanese), a second newsletter (Treatment Guidelines), a drug interactions database, handbooks, software ...
The Medical Letter was founded in 1959 by Arthur Kallet, an engineer, and Dr. Harold Aaron, an internist. In 1932, Kallet had written the book 100,000,000 Guinea Pigs, a best-seller that was partly responsible for the Food and Drug Act of 1938, which required for the first time that new drugs show proof of safety. He was the founding director of Consumers Union and started the publication of Consumer Reports. Dr. Aaron, who became the medical director of Consumer Reports, suggested to Kallet that doctors could use a similar publication to evaluate the new drugs that were coming on the market...
Med Lett Drugs Ther. 2009 Jan 26;51(1304):5 | Show Introduction Hide Introduction